...
首页> 外文期刊>International Journal of Cancer =: Journal International du Cancer >Alterations in classical and nonclassical HLA expression in recurrent and progressive HPV-induced usual vulvar intraepithelial neoplasia and implications for immunotherapy
【24h】

Alterations in classical and nonclassical HLA expression in recurrent and progressive HPV-induced usual vulvar intraepithelial neoplasia and implications for immunotherapy

机译:复发性和进行性HPV引起的普通外阴上皮内瘤变的经典和非经典HLA表达的改变及其对免疫治疗的意义

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Immunotherapy of usual vulvar intraepithelial neoplasia (uVIN) is promising; however, many patients still fail to show clinical responses, which could be explained by an immune escape through alterations in human leukocyte antigen (HLA) expression. Therefore, we analyzed a cohort of patients with a primary (n = 43) and subsequent recurrent uVIN lesion (n = 20), vaccine-treated uVIN patients (n = 12), patients with human papillomavirus (HPV)-induced vulvar carcinoma (n = 21) and healthy controls (n = 26) for the expression of classical HLA-class I/II and nonclassical HLA-E/-G and MHC class I chain-related molecule A (MICA). HLA-class I was downregulated in 70% of uVIN patients, including patients with a clinical response to immunotherapy. Downregulation of HLA-class I is probably reversible, as only 15% of the uVIN cases displayed loss of heterozygosity (LOH) and HLA-class I could be upregulated in uVIN keratinocyte cultures by interferon γ. HLA-class I downregulation is more frequently associated with LOH in vulvar carcinomas (25-55.5%). HLA-class II was found to be focally expressed in 65% of uVIN patients. Of the nonclassical molecules, MICA was downregulated in 80% of uVIN whereas HLA-E and -G were expressed in a minority of cases. Their expression was more prominent in vulvar carcinoma. No differences were found between the alterations observed in paired primary and recurrent uVIN. Importantly, downregulation of HLA-B/C in primary uVIN lesions was associated with the development of recurrences and progression to cancer. We conclude that downregulation of HLA is frequently observed in premalignant HPV-induced lesions, including clinical responders to immunotherapy, and is associated with worse clinical outcome. However, in the majority of cases downregulation may still be reversible.
机译:普通外阴上皮内瘤变(uVIN)的免疫治疗是有前途的;但是,许多患者仍未显示出临床反应,这可以通过人类白细胞抗原(HLA)表达改变而逃脱免疫来解释。因此,我们分析了一组原发性(n = 43)及随后复发的uVIN病变(n = 20),疫苗治疗的uVIN患者(n = 12),人乳头瘤病毒(HPV)诱导的外阴癌( n = 21)和健康对照(n = 26),用于表达经典HLA I / II类和非经典HLA-E / -G和MHC I类链相关分子A(MICA)。在70%的uVIN患者(包括对免疫疗法有临床反应的患者)中,HLA I类下调​​。 HLA I类的下调可能是可逆的,因为只有15%的uVIN病例显示出杂合性(LOH)的丧失,而HLA I类在干扰素γ的uVIN角质形成细胞培养中可能被上调。 HLA-I类下调在外阴癌中更常与LOH相关(25-55.5%)。发现HLA II类在65%的uVIN患者中集中表达。在非经典分子中,MICA在uVIN的80%中被下调,而HLA-E和-G在少数情况下表达。它们的表达在外阴癌中更为突出。在配对的原发性和复发性uVIN中观察到的改变之间没有发现差异。重要的是,原发性uVIN病变中HLA-B / C的下调与复发的发展和癌症的发展有关。我们得出结论,在恶性HPV诱发的病变(包括免疫治疗的临床反应者)中经常观察到HLA的下调,并且与较差的临床结果相关。但是,在大多数情况下,下调仍可能是可逆的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号